Andrew Huberman, a neuroscience professor at Stanford, has stated publicly that "BPC-157 is one of the more interesting peptides because of the gastric juice origin and the acid stability, but the lack of human trials is a real limitation that people tend to overlook." This sentiment reflects the tension between preclinical promise and clinical evidence gaps
doi: 10.1016/j.japh.2023.10.002
PMID: 18 GuoSNJiangXQChenNSongSMFangYXieQMet al
Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J: The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity
2019 Mar 1;102(2):395-411
Summary of revisions: Standards of Care in Diabetes 2026